Investment in quality and assurance of supply
Today’s biotherapeutic producers are transforming lives by making better therapies more accessible. As a result, ensuring the safety and availability of these medicines is paramount. In addition to responding to evolving regulatory requirements, biomanufacturers are adopting comprehensive strategies to help ensure product supply and long-term business continuity. We recognize that as a supplier into your process we play a critical role in supporting your need for high-quality products, a stable supply chain and robust risk mitigation strategies.
Careful planning and inventory management are paramount to ensure critical direct materials are available when needed to avoid potential production delays. Through custom stocking agreements and inventory management, we can help you shorten lead times and improve On Time In Full (OTIF) performance. Learn more.
Worldwide manufacturing network
Our worldwide manufacturing network supports bioprocessing customers in more than 100 countries on six continents. These state-of-the-art facilities are ISO 9001:2015 certified and meet rigorous quality standards. Our sites are audit-ready–hosting hundreds of customer site audits per year.
Production Chemical and Sourcing Services
Discover how to globally source your multi-compendial production chemicals from a limitless portfolio with our bioproduction workflow experts. Learn more.
|Cell culture||Single-use technologies||Purification||Analytical methods||GMP Distribution Facilities|
We are committed to high quality standards and risk mitigation strategies, like redundant manufacturing, in all our manufacturing networks to meet your specific requirements for confidence in your manufacturing processes.
Listen to a customer’s perspective on the significance of working with a reliable partner for redundancy of supply, timing and quality.
To help meet our customers’ risk mitigation requirements related to supply assurance and consistency, we have harmonized our media manufacturing capabilities in Grand Island, NY and Paisley, Scotland for AGT dry media format as well as traditional AOF Dry Powder Medium (DPM) and Bulk Liquid Medium. This strategy not only increases our capacity, it provides us with a significant step forward in executing against our long-term continuity plans. As a result, operational processes, from order entry and creation of documentation, to conversion processes and testing are being aligned to provide our customers a supply stream of equivalent product through redundant sites, regardless of the site of manufacturing origin.
Take a tour of our Grand Island, NY facility and learn more about our recent large volume liquid capacity expansion.